Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 4, 2023 8:21 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.
GUIDANCE:
Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of... More



